Get the Stockscreener App
33.99
2.66%
-0.9852
Dianthus Therapeutics Inc stock is traded at $33.99, with a volume of 396.35K.
It is down -2.66% in the last 24 hours and down -2.55% over the past month.
Dianthus Therapeutics Inc is a clinical-stage biotechnology company dedicated to designing and delivering novel, monoclonal antibodies with improved selectivity and potency over existing complement therapies. The company is focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases. The company is comprised of an experienced team of biotech and pharma executives. The company's pipeline consists of DNTH103 a subcutaneous active C1s antibody.
See More
Previous Close:
$34.98
Open:
$34.52
24h Volume:
396.35K
Relative Volume:
0.59
Market Cap:
$1.09B
Revenue:
$4.85M
Net Income/Loss:
$-114.75M
P/E Ratio:
-10.46
EPS:
-3.25
Net Cash Flow:
$-100.36M
1W Performance:
+1.58%
1M Performance:
-2.55%
6M Performance:
+56.91%
1Y Performance:
+21.56%
1-Day Range:
$32.28
$35.40
1-Week Range:
$32.28
$35.40
52-Week Range:
$13.37
$40.16
Dianthus Therapeutics Inc Stock (DNTH) Company Profile
Name
Dianthus Therapeutics Inc
Sector
Industry
Phone
929-999-4055
Address
7 TIMES SQUARE, NEW YORK
Compare DNTH with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
DNTH
Dianthus Therapeutics Inc
|
33.97 | 1.39B | 4.85M | -114.75M | -100.36M | -3.25 |
|
VRTX
Vertex Pharmaceuticals Inc
|
425.08 | 109.11B | 11.39B | 3.64B | 3.50B | 13.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
641.99 | 68.50B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
432.26 | 60.25B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
822.85 | 50.39B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
183.78 | 40.44B | 447.02M | -1.18B | -868.57M | -6.1812 |
Dianthus Therapeutics Inc Stock (DNTH) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-14-25 | Initiated | Truist | Buy |
| Jul-02-25 | Initiated | William Blair | Outperform |
| Dec-20-24 | Initiated | TD Cowen | Buy |
| Oct-03-24 | Initiated | Oppenheimer | Outperform |
| Jul-26-24 | Initiated | Robert W. Baird | Outperform |
| Jun-27-24 | Initiated | Cantor Fitzgerald | Overweight |
| May-16-24 | Initiated | H.C. Wainwright | Buy |
| Feb-15-24 | Initiated | Stifel | Buy |
| Dec-26-23 | Initiated | Jefferies | Buy |
| Nov-22-23 | Initiated | Wedbush | Outperform |
| Oct-30-23 | Initiated | Guggenheim | Buy |
| Sep-28-23 | Initiated | Raymond James | Outperform |
| Aug-25-22 | Downgrade | Goldman | Buy → Neutral |
| Jan-06-22 | Upgrade | Goldman | Neutral → Buy |
| Aug-20-21 | Resumed | Goldman | Neutral |
| Aug-03-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jul-22-21 | Reiterated | B. Riley Securities | Buy |
| Jun-29-21 | Initiated | Cantor Fitzgerald | Overweight |
| Jun-15-21 | Initiated | BTIG Research | Buy |
| May-18-21 | Initiated | B. Riley Securities | Buy |
| Jan-07-21 | Initiated | Mizuho | Buy |
| Jun-08-20 | Upgrade | Goldman | Neutral → Buy |
| Mar-25-19 | Downgrade | Goldman | Buy → Neutral |
| Mar-15-19 | Initiated | Raymond James | Outperform |
View All
Dianthus Therapeutics Inc Stock (DNTH) Latest News
Dianthus Therapeutics Reports Positive Phase 2 Results - TipRanks
Dianthus Therapeutics, Inc. Updates Corporate Presentation - TradingView
How Dianthus Therapeutics Inc. stock reacts to global recession fearsMarket Growth Report & Smart Allocation Stock Tips - newser.com
Is Dianthus Therapeutics Inc. (87E) stock a fit for income portfoliosNew Guidance & Breakout Confirmation Trade Signals - newser.com
Trend analysis for Dianthus Therapeutics Inc. this weekJuly 2025 Sentiment & Scalable Portfolio Growth Ideas - newser.com
Smart tools for monitoring Dianthus Therapeutics Inc.’s price actionRate Hike & Growth Oriented Trading Recommendations - newser.com
Why Dianthus Therapeutics Inc. stock remains resilientDay Trade & Weekly Market Pulse Updates - newser.com
Will Dianthus Therapeutics Inc. (87E) stock hit Wall Street targetsJuly 2025 Sentiment & Entry Point Confirmation Alerts - newser.com
How to escape a deep drawdown in Dianthus Therapeutics Inc.Gap Up & Growth Focused Stock Reports - newser.com
What recovery options are there for Dianthus Therapeutics Inc.Weekly Earnings Recap & Accurate Intraday Trading Signals - newser.com
Will Dianthus Therapeutics Inc. (87E) stock outperform value peersJuly 2025 Pullbacks & Daily Market Momentum Tracking - newser.com
Using Python tools to backtest Dianthus Therapeutics Inc. strategiesJuly 2025 Opening Moves & Risk Controlled Swing Trade Alerts - newser.com
Will Dianthus Therapeutics Inc. stock see PE expansionJuly 2025 Sector Moves & Daily Entry Point Trade Alerts - newser.com
Will Dianthus Therapeutics Inc. (87E) stock gain from green policiesMarket Risk Summary & Expert Verified Movement Alerts - newser.com
Long term hold vs stop loss in Dianthus Therapeutics Inc.2025 Momentum Check & Fast Moving Stock Watchlists - newser.com
Dianthus Therapeutics Inc. stock chart pattern explainedMarket Risk Report & Community Trade Idea Sharing Platform - newser.com
Using Bollinger Bands to evaluate Dianthus Therapeutics Inc.July 2025 Review & AI Optimized Trade Strategies - newser.com
Can Dianthus Therapeutics Inc. stock hit analyst price targetsWeekly Gains Report & Verified Momentum Stock Alerts - newser.com
Dianthus Therapeutics, Inc. (DNTH) Analyst Insights, Price Targets & Recommendations - Yahoo! Finance Canada
Using economic indicators to assess Dianthus Therapeutics Inc. potentialWeekly Gains Summary & Risk Managed Trade Strategies - newser.com
Dianthus Therapeutics (DNTH) Expected to Announce Quarterly Earnings on Thursday - MarketBeat
What to expect from Dianthus Therapeutics Inc. in the next 30 daysJuly 2025 WrapUp & Daily Entry Point Trade Alerts - newser.com
How to monitor Dianthus Therapeutics Inc. with trend dashboardsWeekly Trend Summary & Risk Controlled Daily Trade Plans - newser.com
Dianthus Therapeutics, Inc. (DNTH) Analyst insights, Price targets and Recommendations - Yahoo! Finance UK
Dianthus Therapeutics, Inc. (DNTH) Expected to Beat Earnings Estimates: Should You Buy? - Yahoo Finance
How New Phase 2 MaGic Data on Claseprubart Has Changed the Investment Story at Dianthus Therapeutics (DNTH) - Sahm
Dianthus Therapeutics Highlights New Claseprubart Data Presented During 2025 AANEM Annual Meeting - The Manila Times
Dianthus Therapeutics Reports Positive Phase 2 MaGic Trial Data for Claseprubart in Generalized Myasthenia Gravis and Plans Phase 3 Trial Initiation in 2026 - Quiver Quantitative
Dianthus (NASDAQ: DNTH) plans Phase 3 gMG with two claseprubart arms and QMG≥10 criterion - Stock Titan
Dianthus Therapeutics Inc Stock (DNTH) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.27%
0.10%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):